药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Ipilimumab
The risk or severity of adverse effects can be increased when Ipilimumab is combined with Polatuzumab vedotin.
Difenoxin
Lumiliximab
The risk or severity of adverse effects can be increased when Lumiliximab is combined with Polatuzumab vedotin.
Difenoxin
Eldelumab
The risk or severity of adverse effects can be increased when Eldelumab is combined with Polatuzumab vedotin.
Difenoxin
IMC-1C11
The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Polatuzumab vedotin.
Difenoxin
Caplacizumab
The risk or severity of adverse effects can be increased when Caplacizumab is combined with Polatuzumab vedotin.
Difenoxin
TB-402
The risk or severity of adverse effects can be increased when TB-402 is combined with Polatuzumab vedotin.
Difenoxin
IPH 2101
The risk or severity of adverse effects can be increased when IPH 2101 is combined with Polatuzumab vedotin.
Difenoxin
Olaratumab
The risk or severity of adverse effects can be increased when Olaratumab is combined with Polatuzumab vedotin.
Difenoxin
Glembatumumab vedotin
The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Polatuzumab vedotin.
Difenoxin
Leronlimab
The risk or severity of adverse effects can be increased when Leronlimab is combined with Polatuzumab vedotin.
Difenoxin
CT-011
The risk or severity of adverse effects can be increased when CT-011 is combined with Polatuzumab vedotin.
Difenoxin
MYO-029
The risk or severity of adverse effects can be increased when MYO-029 is combined with Polatuzumab vedotin.
Difenoxin
RI 624
The risk or severity of adverse effects can be increased when RI 624 is combined with Polatuzumab vedotin.
Difenoxin
TNX-901
The risk or severity of adverse effects can be increased when TNX-901 is combined with Polatuzumab vedotin.
Difenoxin
PRO-542
The risk or severity of adverse effects can be increased when PRO-542 is combined with Polatuzumab vedotin.
Difenoxin
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Polatuzumab vedotin.
Difenoxin
Veltuzumab
The risk or severity of adverse effects can be increased when Veltuzumab is combined with Polatuzumab vedotin.
Difenoxin
Farletuzumab
The risk or severity of adverse effects can be increased when Farletuzumab is combined with Polatuzumab vedotin.
Difenoxin
Ramucirumab
The risk or severity of adverse effects can be increased when Ramucirumab is combined with Polatuzumab vedotin.
Difenoxin
Enokizumab
The risk or severity of adverse effects can be increased when Enokizumab is combined with Polatuzumab vedotin.